Xspray Pharma: HyNap-Dasa 505(b)(2) has reached BE - Redeye

Redeye leaves a comment on Xspray following the announcement that its HyNap-Dasa 505(b)(2) reached bioequivalence compared to its reference drug Sprycel. We raise our Base Case.

https://www.redeye.se/research/817840/xspray-pharma-initial-take-on-hynap-dasa-505b2-reaching-be?utm_source=finwire&utm_medium=RSS